Thrombocytopenia Caused by Abciximab or Tirofiban and Its Association with Clinical Outcome in Patients Undergoing Coronary Stenting

Circulation

Volumn 109, Issue 18, 2004, Pages 2203-2206

  Merlini, Piera Angelica ^a   Rossi, Marco ^b   Menozzi, Alberto ^c   Buratti, Silvia ^c   Brennan, Danielle M ^e   Moliterno, David J ^d   Topol, Eric J ^e   Ardissino, Diego ^c  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c Ospedale di Parma   (Italy)

^d UNIVERSITY OF KENTUCKY   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anticoagulants; Platelets; Stents; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DEATH; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; FEMALE; GENDER; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; BLOOD TRANSFUSION; COMBINED MODALITY THERAPY; CORONARY STENOSIS; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; RISK FACTORS; STENTS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TYROSINE;

EID: 2442570825     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000127867.41621.85     Document Type: Article

References (13)

1. Dasgupta H, Blankenship JC, Wood C, et al. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J. 2000;140:206-211.
2. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J. 2000;139:S38-S45.
3. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
4. Llevadot J, Coulter SA, Giuliano RP. A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb Thrombolysis. 2000;9: 175-180.
5. Jubelirer SJ, Koenig BA, Bates MC. Acute profound thrombocytopenia following C7E3 Fab therapy: case reports, review of the literature and implications for therapy. Am J Hematol. 1999;61:205-208.
6. Tcheng JE, Kereiakes DJ, Linkoff M, et al. Abciximab readministration: results of the Reopro Readministration Registry. Circulation. 2001;104: 870-875.
7. Nguyen N, Salib H, Mascarenhas DA. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab. J Invasive Cardiol. 2000;13:56-58.
8. Desai M, Lucore CL. Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab-associated thrombocytopenia 10 months earlier. J Invasive Cardiol. 2000;12: 109-112.
9. Dillon WC, Eckert GJ, Dillon JC, et al. Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel and ticlopidine. Cathet Cardiovasc Interv. 2000;50:426-430.
10. Kereiakes DJ, Berkowitz SD, Lincoff MA, et al. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J. 2000;140:74-80.
11. Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol. 1998;32: 311-319.
12. Eikelboom JW, Anand SS, Mehta SR, et al. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndromes without ST elevation: OASIS-2 study. Circulation. 2001;103: 643-650.
13. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical significance of thrombocytopenia during non-ST-elevation acute coronary syndromes: the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Experience. Circulation. 1999;99:2892-2900.